Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.

Zheng G, Ning J, Yang YC.

Biochem Biophys Res Commun. 2007 Dec 14;364(2):344-50. Epub 2007 Oct 11.

PMID:
17950244
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Making sense of ubiquitin ligases that regulate p53.

Jain AK, Barton MC.

Cancer Biol Ther. 2010 Oct 1;10(7):665-72. Epub 2010 Oct 1. Review.

PMID:
20930521
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A novel oncoprotein Pirh2: rising from the shadow of MDM2.

Wang Z, Yang B, Dong L, Peng B, He X, Liu W.

Cancer Sci. 2011 May;102(5):909-17. doi: 10.1111/j.1349-7006.2011.01899.x. Epub 2011 Feb 28. Review.

PMID:
21284766
[PubMed - indexed for MEDLINE]
4.

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

Jung YS, Qian Y, Chen X.

FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3. Review.

PMID:
22673504
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

p53 ubiquitination: Mdm2 and beyond.

Brooks CL, Gu W.

Mol Cell. 2006 Feb 3;21(3):307-15. Review.

PMID:
16455486
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

p53 proteasomal degradation: poly-ubiquitination is not the whole story.

Asher G, Shaul Y.

Cell Cycle. 2005 Aug;4(8):1015-8. Epub 2005 Aug 7. Review.

PMID:
16082197
[PubMed - indexed for MEDLINE]
Free Article
7.

A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.

Satija YK, Bhardwaj A, Das S.

Int J Cancer. 2013 Dec 15;133(12):2759-68. doi: 10.1002/ijc.28129. Epub 2013 Mar 25. Review.

PMID:
23436247
[PubMed - indexed for MEDLINE]
8.

Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.

Allende-Vega N, Saville MK.

Semin Cancer Biol. 2010 Feb;20(1):29-39. doi: 10.1016/j.semcancer.2009.10.004. Epub 2009 Nov 6. Review.

PMID:
19897040
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk